Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCI | P41743 | 8/20 | 0.47 |
| ▸ | ATR | Q13535 | 1/20 | 0.47 |
| ▸ | GRM5 | P41594 | 1/20 | 0.44 |
| ▸ | TLR7 | Q9NYK1 | 3/20 | 0.41 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.38 |
| ▸ | GBA1 | P04062 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | PIM1 | P11309 | 1/20 | 0.36 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.36 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | VCP | P55072 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL698878 | 0.87 | TSHR (0.37) | PRKCIATRGRM5TLR7NAPRT | |
| SCHEMBL27669301 | 0.80 | PRKCI (0.50) | PRKCIATRGRM5TLR7NAPRT | |
| SCHEMBL30065824 | 0.78 | PRKCI (0.48) | PRKCIATRGRM5TLR7NAPRT | |
| SCHEMBL29578557 | 0.78 | ATR (0.53) | PRKCIATRGRM5TLR7NAPRT | |
| SCHEMBL20853598 | 0.78 | PRKCI (0.48) | PRKCIATRGRM5TLR7NAPRT | |
| SCHEMBL1097431 | 0.78 | PRKCI (0.48) | PRKCIATRGRM5TLR7NAPRT | |
| SCHEMBL65106 | 0.78 | ATR (0.53) | PRKCIATRGRM5TLR7NAPRT | |
| SCHEMBL13697278 | 0.78 | PDE3B (0.39) | PRKCIATRGRM5L3MBTL1KDM4E | |
| SCHEMBL24845445 | 0.76 | PRKCI (0.39) | PRKCIATRGRM5TLR7GBA1 | |
| SCHEMBL3292931 | 0.76 | PRKCI (0.47) | PRKCIATRGRM5TLR7NAPRT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9388183-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2016-07-12 | — | — | US | disclosed |
| US-9388183-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2016-07-12 | — | — | US | disclosed |
| US-20150031672-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INFINITY PHARMACEUTICALS, INC. | 2015-01-29 | — | — | US | disclosed |
| US-20150031672-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INFINITY PHARMACEUTICALS, INC. | 2015-01-29 | — | — | US | disclosed |
| US-8901133-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2014-12-02 | — | — | US | disclosed |
| US-8901133-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2014-12-02 | — | — | US | disclosed |
| WO-2012064973-A2 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INFINITY PHARMACEUTICALS, INC. (US) | 2012-05-18 | — | — | WO | disclosed |
| US-20120122838-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INFINITY PHARMACEUTICALS, INC. | 2012-05-17 | — | — | US | disclosed |
| US-20120122838-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INFINITY PHARMACEUTICALS, INC. | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150031672-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | PRKCI 117/4885ATR 669/4885GRM5 2952/4885 |
| US-20120122838-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | PRKCI 117/4885ATR 669/4885GRM5 2952/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.